cambrex

cambrex公司的产品由上海拜力生物科技有限公司代理销售。

cambrex公司详细产品信息请联系 电话：

021-33779006 33779008 86220963

企业QQ：800050007 QQ：3069954

邮箱：fuwu@bioleaf.com

cambrex官方网站 www.cambrex.com

cambrex简介

Cambrex

Cambrex About

Cambrex Corporation is an innovative life sciences company providing products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.

We offer a variety of technology-driven products and services for generic and branded pharmaceuticals:

APIs

Advanced intermediates

Drug delivery products

Custom development and manufacturing

Our R&D and cGMP manufacturing facilities are located in the US, Europe and India. We are committed to operating our facilities with the highest standards of:

Regulatory compliance

Environmental, health and safety guidelines

Cambrex Corporation is headquartered in East Rutherford, NJ, USA and is listed on the NYSE (CBM).

Cambrex Mission

Cambrex provides innovative solutions for established and emerging pharmaceutical and biotech companies with clinical or commercial API needs.

Cambrex is an experienced supplier of small molecule products and services to the life sciences industry.

Our technologies accelerate and improve product development for our clients.

We operate within the industry’s highest quality standards, with uncompromising integrity and ethics.

We have the greatest respect for our employees, the environment and the communities in which we live and work.

History

Cambrex has positioned our product and custom development pipelines to leverage our API, drug delivery and formulation capabilities to develop technology advanced products. Our diverse small molecule portfolio helps us to expand into growing developing markets and advance our niche products and technologies.

Cambrex has transformed from a fine chemical manufacturer since its creation in 1981 – and we continue to pursue acquisitions and partnerships that improve the utilization of our manufacturing facilities, lower our cost structure and provide access to value added tools or IP and low cost R&D. This results in Cambrex being a streamlined business with singular focus on small molecule therapeutics.

2010

To broaden biocatalysis and NRT offerings to the pharmaceutical industry, Cambrex acquires IEP GmbH; now Cambrex IEP and Zenara Pharma, Ltd; now Cambrex Zenara.

2009

Cambrex Karlskoga completes the addition of a new cGMP API production facility.

2008

Cambrex expands their group of world class R&D chemists by acquiring Prosyntest; renamed Cambrex Tallinn. Steven M. Klosk is appointed to CEO while remaining President. Cambrex Charles City completes the addition of a high potency development center.

2007

Cambrex exits the biologics market and re-focuses on small molecule APIs and intermediates at its three manufacturing facilities: Cambrex Karlskoga, Cambrex Profarmaco, and Cambrex Charles City. Cambrex Profarmaco completes the expansion of the R&D lab and the additions of a new purification department and warehouse.

2003

The company dedicates itself to providing essential products and services that accelerate drug discovery, development and manufacturing of human therapeutics.

2002

To support the Companys strategic emphasis on the growing opportunities in the life sciences industry, Cambrex launches a new corporate identity. Cambrex obtains DEA licensing for Controlled Substance API manufacturing.

2001

Cambrex enters the biologics manufacturing market with the acquisition of two contract biopharmaceutical manufacturing facilities. The facilities produce purified bulk biologics and pharmaceutical ingredients from clinical to commercial scale.

2000

Cambrex continues its growth into the life sciences and biologics industries through the acquisitions of a chiral enzymatic catalyst business and a bioscience products facility in Belgium.

1999

Cambrex enters the growing fields of molecular biology and proteomics through the acquisition of the FMC Bioproducts business. In addition to bioscience, this acquisition further strengthens the API and advanced intermediates manufacturing capacity.

1997

Cambrex enters the biologics markets with the acquisition of BioWhittaker, a life sciences company that provides cell culture and endotoxin detection products.

1994

Cambrex further penetrates the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry businesses, Nobel Chemicals AB and Profarmaco S.r.l. The business units are later renamed Cambrex Karlskoga and Cambrex Profarmaco.

1991

The Company enters the life sciences arena with the acquisition of Salsbury Chemicals, a manufacturer of bulk intermediates and APIs, as well as high-level research in nitration chemistry, and Zeeland Chemicals, producer of specialty intermediates and hydrogenation chemistry.

1990

James A. Mack is hired as President and CEO. Cambrex is listed on the New York Stock Exchange (NYSE).

1987

The Company changes its name to Cambrex Corporation and becomes listed on the NASDAQ.

1981

Originally named CasChem, the Company is founded when the castor oil and derivatives product lines are acquired from NL Industries.

cambrex产品代理公司上海拜力科技有限公司简介详情

上海拜力生物科技有限公司——依托复旦大学，集研发、销售、实验室技术服务于一体的高科技企业。 专业经营进口胎牛血清、细胞因子、ELISA试剂盒等实验室试剂、化工产品、实验室消耗品、实验室耗材以及实验室器材 。产品涉及分子生物学、细胞生物学、细菌学、遗传学、免疫学、生物化学、蛋白质学、细胞治疗、临床应用等领域。 主要产品及服务： 血清 细胞 抗体 细胞因子 试剂盒 实验试剂 实验耗材 技术服务 实验仪器

实验技术服务内容

1.病理学服务项目

1）石蜡包埋、石蜡切片、冰冻切片、骨包埋切片、骨切片染色

2）HE染色、PAS染色、甲苯胺蓝染色

3）免疫组化化学实验

4）原位杂交实验、TUNEL检测、端粒酶活性检测

2.免疫方面相关技术服务

1）酶联免疫（ELISA)检验

2）多克隆抗血清制备

3）单克隆抗体制备、抗体纯化、抗体标记

4）蛋白免疫印迹技术服务

3.分子生物学类实验

1）分子标记--AFLP、SSR、STR、ISSR、SRAP、RAPD、SCAR、SSCP、STS、CAPS

2）核酸提取--基因组DNA提取、总RNA提取、质粒DNA提取

3）PCR扩增及产物纯化

4）实时荧光定量及半定量RT-PCR

5）基因克隆、载体构建表达和纯化、文库构建、分子杂交、miRNA相关实验

4.细胞生物学相关技术服务

1）细胞培养、传代和冻存，细胞转染，药物干扰，细胞浸染

2) 采用MTT方法进行细胞毒实验，细胞检测

3）流式细胞术检测

5.动物实验，动物生化/放**测 6.DAN测序及引物合成

cambrex产品是由上海拜力生物科技有限公司代理销售。

若您需要cambrex产品、想要了解更多产品信息或订购、技术等服务。

联系我们，我们的cambrex产品负责人会**时间与您解需。

手机：13764559528

传真：021-65538480

邮编：200240

地址：上海市闵行区金平路788弄166号